Actively Recruiting
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
Led by Dartmouth-Hitchcock Medical Center · Updated on 2025-10-20
192
Participants Needed
1
Research Sites
297 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-arm Phase II study to measure the impact of Molecular Tumor Board treatment recommendations on treatment decision-making in clinical practice at the Dartmouth Cancer Center. Following tumor genetic profiling, subjects will be screened for eligibility. Eligible subjects' cases will be evaluated by the Dartmouth Cancer Center Molecular Tumor Board, and treatment recommendations will be entered into the medical record as per standard procedure. The primary endpoint is a survey response from the treating physician indicating how Molecular Tumor Board evaluation impacted treatment decisions. Secondary endpoints include: 1) Molecular Tumor Board treatment recommendation; 2) disease progression on line of therapy started after MTB recommendations were made. Surveys will be administered approximately 3 and 12 months after Molecular Tumor Board recommendations are made.
CONDITIONS
Official Title
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subject must provide verbal informed consent for study participation prior to Molecular Tumor Board case evaluation.
- Tumor genetic profiling performed as standard of care must include at least 100 genes.
- Tumor must contain at least one genetic alteration: (A) known to be potentially associated with sensitization to a clinically available treatment; or (B) suspected to be germline.
- Subject must have ECOG Performance Status of 0 to 2.
- Subject must have measurable or evaluable disease.
- Subjects previously enrolled can be re-enrolled if they have new tumor genetic profiling after progression on intervening treatment.
- Age 18 years or older.
You will not qualify if you...
- Subjects with a tumor genetic alteration for which an FDA-approved drug is indicated that the patient has not yet received.
- Pregnant women.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Actively Recruiting
Research Team
L
Laura J Tafe, MD
CONTACT
J
Jacob R Dubien
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here